Sebia, a global specialty diagnostic company, develops, manufactures and commercializes IVD tests & analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, diabetes and hemoglobinopathies. Sebia focuses on agarose gel & capillary electrophoresis techniques designed to be integrated into the lab workflow. Sebia is continuously investing in innovations dedicated to Multipe Myeloma with HYDRASHIFT dara/isa to mitigate drug interferences, Sebia FLC Kappa/ Lambda assays and MRD testing.
Sebia, a global specialty diagnostic company, develops, manufactures and commercializes IVD tests and analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, diabetes and hemoglobin disorders. Sebia focuses on electrophoresis techniques on agarose gel and capillary assays designed to be integrated into the lab workflow. Recently Sebia completed their Myeloma portfolio: Hydrashift Dara/Isa to mitigate drug interferences and a new generation Sebia FLC kappa/Lambda assays.